miR‑769‑5p is associated with prostate cancer recurrence and modulates proliferation and apoptosis of cancer cells

Lee,Daniel

doi:10.3892/etm.2021.9766

miR‑769‑5p is associated with prostate cancer recurrence and modulates proliferation and apoptosis of cancer cells

Authors:
- Daniel Lee
View Affiliations

Affiliations: Medical Oncology Service and The Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Published online on: February 8, 2021 https://doi.org/10.3892/etm.2021.9766
Article Number: 335
Copyright: © Lee . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRs) are relevant in biological processes, including human prostate cancer. In the present study, the role of miR‑769‑5p and its targets in prostate cancer were explored. Publicly available data on expression of genes, miRs and disease‑free survival of patients with prostate cancer were analyzed along with RNAseq of transfected cell lines. miR‑769‑5p expression was inversely associated with patient survival and in vitro assays indicated that its inhibition reduced the proliferation and increased apoptosis of prostate cancer cells. miR‑769‑5p was revealed to target Rho GTPase activating protein 10 (ARHGAP10) and increased expression of ARHGAP10 in tumors was determined to be associated with a favorable prognosis regarding disease‑free survival. Of note, ARHGAP10 is a purported tumor suppressor in ovarian cancer, where it inhibits cell division cycle 42 (CDC42) activity and increases apoptosis. Similar effects were observed in prostate cancer cells, where miR‑769‑5p inhibition increased ARHGAP10 and led to reduced CDC42 activity. Furthermore, miR‑769‑5p inhibition increased apoptosis, which was partly reversed by additional knockdown of ARHGAP10. These results suggested that miR‑769‑5p is an oncogene targeting ARHGAP10, which in turn is a candidate tumor suppressor in prostate cancer.

View Figures

View References

1	Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993.PubMed/NCBI View Article : Google Scholar
2	Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB, et al: MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res. 40:3689–3703. 2012.PubMed/NCBI View Article : Google Scholar
3	Hudson RS, Yi M, Esposito D, Glynn SA, Starks AM, Yang Y, Schetter AJ, Watkins SK, Hurwitz AA, Dorsey TH, et al: MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. Oncogene. 32:4139–4147. 2013.PubMed/NCBI View Article : Google Scholar
4	Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, et al: Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 68:6162–6170. 2008.PubMed/NCBI View Article : Google Scholar
5	Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al: Integrative genomic profiling of human prostate cancer. Cancer Cell. 18:11–22. 2010.PubMed/NCBI View Article : Google Scholar
6	Schultz NA, Andersen KK, Roslind A, Willenbrock H, Wojdemann M and Johansen JS: Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer-five microRNAs in a prognostic index. World J Surg. 36:2699–2707. 2012.PubMed/NCBI View Article : Google Scholar
7	Xie H, Lee L, Caramuta S, Höög A, Browaldh N, Björnhagen V, Larsson C and Lui WO: MicroRNA expression patterns related to merkel cell polyomavirus infection in human merkel cell carcinoma. J Invest Dermatol. 134:507–517. 2014.PubMed/NCBI View Article : Google Scholar
8	Gasparini P, Cascione L, Landi L, Carasi S, Lovat F, Tibaldi C, Alì G, D'Incecco A, Minuti G, Chella A, et al: MicroRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers. Proc Natl Acad Sci USA. 112:14924–14929. 2015.PubMed/NCBI View Article : Google Scholar
9	Yang Z, He J, Gao P, Niu Y, Zhang J, Wang L, Liu M, Wei X, Liu C, Zhang C, et al: miR-769-5p suppressed cell proliferation, migration and invasion by targeting TGFBR1 in non-small cell lung carcinoma. Oncotarget. 8:113558–113570. 2017.PubMed/NCBI View Article : Google Scholar
10	Luo N, Guo J, Chen L, Yang W, Qu X and Cheng Z: ARHGAP10, downregulated in ovarian cancer, suppresses tumorigenicity of ovarian cancer cells. Cell Death Dis. 7(e2157)2016.PubMed/NCBI View Article : Google Scholar
11	Gong H, Chen X, Jin Y, Lu J, Cai Y, Wei O, Zhao J, Zhang W, Wen X, Wang Y and Chen W: Expression of ARHGAP10 correlates with prognosis of prostate cancer. Int J Clin Exp Pathol. 12:3839–3846. 2019.PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
13	Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al: The mutational landscape of lethal castration-resistant prostate cancer. Nature. 487:239–243. 2012.PubMed/NCBI View Article : Google Scholar
14	Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, et al: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA. 101:811–816. 2004.PubMed/NCBI View Article : Google Scholar
15	Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, et al: Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 1:203–209. 2002.PubMed/NCBI View Article : Google Scholar
16	Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell. 163:1011–1025. 2015.PubMed/NCBI View Article : Google Scholar
17	Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, et al: Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 39:41–51. 2007.PubMed/NCBI View Article : Google Scholar
18	Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA and Ambs S: Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 68:927–936. 2008.PubMed/NCBI View Article : Google Scholar
19	Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, et al: Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol. 22:2790–2799. 2004.PubMed/NCBI View Article : Google Scholar
20	Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY and Cheng JQ: Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 33:679–689. 2014.PubMed/NCBI View Article : Google Scholar
21	Gu Y, Liu S, Zhang X, Chen G, Liang H, Yu M, Liao Z, Zhou Y, Zhang CY, Wang T, et al: Oncogenic miR-19a and miR-19b co-regulate tumor suppressor MTUS1 to promote cell proliferation and migration in lung cancer. Protein Cell. 8:455–466. 2017.PubMed/NCBI View Article : Google Scholar
22	Long MD, Singh PK, Russell JR, Llimos G, Rosario S, Rizvi A, van den Berg PR, Kirk J, Sucheston-Campbell LE, Smiraglia DJ and Campbell MJ: The miR-96 and RARγ signaling axis governs androgen signaling and prostate cancer progression. Oncogene. 38:421–444. 2019.PubMed/NCBI View Article : Google Scholar
23	Ren D, Yang Q, Dai Y, Guo W, Du H, Song L and Peng X: Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway. Mol Cancer. 16(117)2017.PubMed/NCBI View Article : Google Scholar
24	Barros-Silva D, Costa-Pinheiro P, Duarte H, Sousa EJ, Evangelista AF, Graça I, Carneiro I, Martins AT, Oliveira J, Carvalho AL, et al: MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis. Cell Death Dis. 9(167)2018.PubMed/NCBI View Article : Google Scholar
25	Huang Q, Ma B, Su Y, Chan K, Qu H, Huang J, Wang D, Qiu J, Liu H, Yang X and Wang Z: miR-197-3p represses the proliferation of prostate cancer by regulating the VDAC1/AKT/β-catenin signaling axis. Int J Biol Sci. 16:1417–1426. 2020.PubMed/NCBI View Article : Google Scholar
26	Geng Y, Deng L, Su D, Xiao J, Ge D, Bao Y and Jing H: Identification of crucial microRNAs and genes in hypoxia-induced human lung adenocarcinoma cells. Onco Targets Ther. 9:4605–4616. 2016.PubMed/NCBI View Article : Google Scholar
27	Chen S, Evans HG and Evans DR: FAM129B/MINERVA, a novel adherens junction-associated protein, suppresses apoptosis in HeLa cells. J Biol Chem. 286:10201–10209. 2011.PubMed/NCBI View Article : Google Scholar
28	Detournay O and Weis VM: Role of the sphingosine rheostat in the regulation of cnidarian-dinoflagellate symbioses. Biol Bull. 221:261–269. 2011.PubMed/NCBI View Article : Google Scholar
29	Hug H, Los M, Hirt W and Debatin KM: Rhodamine 110-linked amino acids and peptides as substrates to measure caspase activity upon apoptosis induction in intact cells. Biochemistry. 38:13906–13911. 1999.PubMed/NCBI View Article : Google Scholar